AstraZeneca entered into a definitive agreement Friday to buy ZS Pharma, a California biotechnology company, for $2.7 billion.
ZS Pharma (NASDAQ: ZSPH) of San Mateo, Calif., has an application seeking approval for ZS-9, its experimental treatment for hyperkalaemia, under review with the Food and Drug Administration. A European marketing application is expected before the end of the year.
{iframe}http://www.bizjournals.com/philadelphia/morning_roundup/2015/11/astrazeneca-buy-zs-pharma-california-27-billion.html?ana=e_phil_bn_breakingnews&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1446841309{/iframe}